Stock Market

Analysts See Steady Growth For Acadia Pharma’s Nuplazid

  • Acadia Pharmaceuticals Inc (NASDAQ: ACAD) reported a Q4 EPS loss of $(0.26), missing the consensus of $(0.24) and sales of $136.49 million, beating the consensus of $134.07 million.

  • For FY23, the company expects Nuplazid sales of $520-$550 million compared to a consensus of $569.16 million.

  • Raymond James, maintaining a Market Perform rating, writes that 2023 revenue guidance does not include potential contributions from trofinetide, with a PDUFA date of March 12 for Rett Syndrome. The analyst projects around $14.5 million in trofinetide revenues in 2023.

  • Given the lack of treatment options for Rett patients, if approved, there may be strong early demand for trofinetide. However, a high attrition rate is expected, given its AE profile and modest benefits.

  • Beyond Rett, ACP-204 (next-generation pimavanserin) is exciting but awaits de-risking data before attributing value to the asset.

  • Needham writes that while the management sees signs of stabilization in the PDP market, it is not yet seeing definitive signs of recovery. The analyst expects the lower-than-expected Nuplazid guidance to drive some weakness in the stock.

  • Overall, it remains on the sidelines to foresee limited upside vs. cons. for Nuplazid sales in the near term and trofinetide launch.

  • The analyst keeps a Hold rating.

  • Cantor Fitzgerald reiterates its Overweight rating and increases the price target to $28 from $27.

  • The analyst is optimistic about the revenue beat following the 3Q22 miss, with new patient adds in long-term care facilities on a vector to returning to pre-pandemic levels.

  • The analyst also notes recent publications pointing to real-world evidence supporting Nuplazid’s differentiated clinical profile, which might provide modest but steady sales growth in 2023.

  • Price Action: ACAD shares are up 10.72% at $21.48 on the last check Tuesday.

Latest Ratings for ACAD






Mar 2022

Cantor Fitzgerald



Mar 2022

Goldman Sachs



Mar 2022




View More Analyst Ratings for ACAD

View the Latest Analyst Ratings

Don’t miss real-time alerts on your stocks – join Benzinga Pro for free! Try the tool that will help you invest smarter, faster, and better.

This article Analysts See Steady Growth For Acadia Pharma’s Nuplazid originally appeared on


© 2023 Benzinga does not provide investment advice. All rights reserved.


Share this news on your Fb,Twitter and Whatsapp

File source

Times News Network:Latest News Headlines
Times News Network||Health||

Show More

Related Articles

Leave a Reply

Your email address will not be published. Required fields are marked *

Back to top button